Compare LIQT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | GRDX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Denmark | United Kingdom |
| Employees | N/A | 2 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 28.6M |
| IPO Year | 2011 | N/A |
| Metric | LIQT | GRDX |
|---|---|---|
| Price | $0.68 | $3.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | ★ 213.6K | 68.4K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.12 | N/A |
| Revenue Next Year | $63.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $1.87 |
| 52 Week High | $3.35 | $6.93 |
| Indicator | LIQT | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 39.17 |
| Support Level | N/A | $2.01 |
| Resistance Level | $1.00 | $5.30 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 3.71 | 6.11 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.